Antagonists Targeting miR-155 and miR-125a Relieved Ultrasonographic Contrast Medium SonoVue Induced Kidney Injury

Pharmaceutical sciences- Pharma

Authors

  • Zhenqiang Yao Department of Ultrasound, Gansu Provincial Hospital, No. 204 Dong Gangxi Road, Lanzhou, Gansu 730000, China
  • Zhengshun Zhang Department of Ultrasound, Baiyin Integrated Traditional Chinese and Western Medicine Hospital

DOI:

https://doi.org/10.22376/ijlpr.2023.13.6.P310-P317

Keywords:

kidney injury, ultrasonographic contrast medium, miR-155 and miR-125a antagonists, NF-kappa B signaling

Abstract

Ultrasonographic contrast medium (UCM) enhances radiological procedures. However, it raises a serious problem thatUCM induces acute kidney injury. However, the mechanism of kidney injury induced by ultrasonographic contrast medium remainselusive. This work aims to explore kidney injury from a post-transcription view. UCM was identified to induce kidney injury byactivating NF-kappa B signaling. The expression of NF-kappa B was examined in mouse kidneys by western blot. The level of NFkappa B was upregulated in the kidney with the treatment of UCM. Hereof, the expression levels of miR-155 and miR-125a,upstream of NF-kappa B, increased significantly in the UCM group, which RT-PCR detects. As a positive control, LPS was used toinduce acute kidney injury. The expressions of NF-kappa B, miR-155, and miR-125a all increased in the LPS group. Further, to verifythe necessity of NF-kappa B signaling in the process of UCM-induced kidney injury, the mice were treated with the antagonists ofmiR-155 and miR-125a, and our results showed that the antagonists of miR-155 and miR-125a repressed NF-kappa B signaling bywestern blot analysis. In conclusion, our results demonstrate that miR-155 and miR-125a antagonists mediate NF-kappa B signalingto relieve kidney injury, which UCM induced. The antagonists would be further tested to alleviate kidney injury clinically.

References

Kiss N, Hamar P. Histopathological evaluation of contrast-induced acute kidney injury rodent models. BioMed Res Int. 2016;2016:3763250. doi: 10.1155/2016/3763250, PMID 27975052.

Tsamouri MM, Rapti M, Kouka P, Nepka C, Tsarouhas K, Soumelidis A, et al. Histopathological evaluation and redox assessment in blood and kidney tissues in a rabbit contrast-induced nephrotoxicity model. Food Chem Toxicol. 2017;108(A):186-93. doi: 10.1016/j.fct.2017.07.058, PMID 28774741.

Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al. Contrast-induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21(12):2527-41. doi: 10.1007/s00330-011-2225-0, PMID 21866433.

Sadat U, Usman A, Boyle JR, Hayes PD, Solomon RJ. Contrast medium-induced acute kidney injury. Cardiorenal Med. 2015;5(3):219-28. doi: 10.1159/000430770, PMID 26195974.

Sun W, Li Z, Zhou X, Yang G, Yuan L. Efficient exosome delivery in refractory tissues assisted by ultrasound-targeted microbubble destruction. Drug Deliv. 2019;26(1):45-50. doi: 10.1080/10717544.2018.1534898, PMID 30744440.

Cao W, Cui S, Yang L, Wu C, Liu J, Yang F, et al. Contrast-enhanced ultrasound for assessing renal perfusion impairment and predicting acute kidney injury to chronic kidney disease progression. Antioxid Redox Signal. 2017;27(17):1397-411. doi: 10.1089/ars.2017.7006, PMID 28715949.

Niu X, Yao Q, Li W, Zang L, Li W, Zhao J, et al. Harmine mitigates LPS-induced acute kidney injury through inhibition of the TLR4-NF-κB/NLRP3 inflammasome signalling pathway in mice. Eur J Pharmacol. 2019;849:160-9. doi: 10.1016/j.ejphar.2019.01.062, PMID 30716318.

Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A. 2012;109(20):7865-70. doi: 10.1073/pnas.1200081109, PMID 22550173.

Tong L, Yuan Y, Wu S. Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers. Adv Drug Deliv Rev. 2015;81:1-15. doi: 10.1016/j.addr.2014.09.004, PMID 25220353.

Liu Y, Li Y, Ren Z, Si W, Li Y, Wei G, et al. MicroRNA-125a-3p is involved in early behavioral disorders in stroke-afflicted rats through the regulation of Cadm2. Int J Mol Med. 2017;40(6):1851-9. doi: 10.3892/ijmm.2017.3179, PMID 29039453.

Liu G, Ji L, Ke M, Ou Z, Tang N, Li Y. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Biomed Pharmacother. 2018;106:523-31. doi: 10.1016/j.biopha.2018.06.114, PMID 29990840.

Zheng L, Meng X, Li X, Zhang Y, Li C, Xiang C, et al. miR-125a-3p inhibits ERalpha transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer. FASEB J. 2018;32(2):588-600. doi: 10.1096/fj.201700461RR, PMID 28939591.

Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol. 2013;6:6. doi: 10.1186/1756-8722-6-6, PMID 23321005.

Kim TH, Seo YS, Kang SH, Kim MY, Kim SG, Lee HY, et al. Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: a multicentre prospective study. Liver Int. 2020;40(12):3083-92. doi: 10.1111/liv.14631, PMID 32750739.

Stenberg B, Talbot D, Khurram M, Kanwar A, Ray C, Mownah O, et al. A new technique for assessing renal transplant perfusion preoperatively using contrast-enhanced ultrasound (CEUS) and three-dimensional ultrasound (3DUS)--a porcine model pilot study. Ultraschall Med. 2011;32;Suppl 2:E8-13. doi: 10.1055/s-0031-1281650, PMID 22179806.

Scarfe L, Rak-Raszewska A, Geraci S, Darssan D, Sharkey J, Huang J, et al. Measures of kidney function by minimally invasive techniques correlate with histological glomerular damage in SCID mice with adriamycin-induced nephropathy. Sci Rep. 2015;5:13601. doi: 10.1038/srep13601, PMID 26329825.

Linta N, Baron Toaldo M, Bettini G, Cordella A, Quinci M, Pey P, et al. The feasibility of contrast-enhanced ultrasonography (CEUS) in the diagnosis of non-cardiac thoracic disorders of dogs and cats. BMC Vet Res. 2017;13(1):141. doi: 10.1186/s12917-017-1061-0, PMID 28545570.

Cai Z, Li S, Li S, Song F, Zhang Z, Qi G, et al. Antagonist targeting microRNA-155 protects against lithium-pilocarpine-induced status epilepticus in C57BL/6 mice by activating brain-derived neurotrophic factor. Front Pharmacol. 2016;7:129. doi: 10.3389/fphar.2016.00129, PMID 27303295.

Chen DQ, Cao G, Chen H, Argyopoulos CP, Yu H, Su W, et al. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nat Commun. 2019;10(1):1476. doi: 10.1038/s41467-019-09329-0, PMID 30931940.

Sasaki Y, Iwama R, Sato T, Heishima K, Shimamura S, Ichijo T, et al. Estimation of glomerular filtration rate in conscious mice using a simplified equation. Physiol Rep. 2014;2(8). doi: 10.14814/phy2.12135, PMID 25168878.

Poveda J, Tabara LC, Fernandez-Fernandez B, Martin-Cleary C, Sanz AB, Selgas R, et al. TWEAK/Fn14 and non-canonical NF-kappaB signaling in kidney disease. Front Immunol. 2013;4:447. doi: 10.3389/fimmu.2013.00447, PMID 24339827.

Ren Y, Song Z, Rieser J, Ackermann J, Koch I, Lv X, et al. USP15 represses hepatocellular carcinoma progression by regulation of pathways of cell proliferation and cell migration: A system biology analysis. Cancers. 2023;15(5):1371. doi: 10.3390/cancers15051371, PMID 36900163.

Published

2023-11-01

How to Cite

Yao, Z. ., & Zhang, Z. . (2023). Antagonists Targeting miR-155 and miR-125a Relieved Ultrasonographic Contrast Medium SonoVue Induced Kidney Injury : Pharmaceutical sciences- Pharma. International Journal of Life Science and Pharma Research, 13(6), P310-P317. https://doi.org/10.22376/ijlpr.2023.13.6.P310-P317

Issue

Section

Research Articles